KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $1.4 billion.

  • Emergent BioSolutions' Liabilities and Shareholders Equity fell 1.14% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 billion, marking a year-over-year decrease of 13.96%. This contributed to the annual value of $1.4 billion for FY2024, which is 23.78% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Liabilities and Shareholders Equity of $1.4 billion as of FY2024, which was down 23.78% from $1.8 billion recorded in FY2023.
  • Emergent BioSolutions' Liabilities and Shareholders Equity's 5-year high stood at $3.2 billion during FY2022, with a 5-year trough of $1.4 billion in FY2024.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $1.8 billion (2023), whereas its average is $2.1 billion.
  • Per our database at Business Quant, Emergent BioSolutions' Liabilities and Shareholders Equity climbed by 23.89% in 2020 and then tumbled by 42.42% in 2023.
  • Emergent BioSolutions' Liabilities and Shareholders Equity (Yearly) stood at $2.9 billion in 2020, then increased by 2.58% to $3.0 billion in 2021, then increased by 7.05% to $3.2 billion in 2022, then plummeted by 42.42% to $1.8 billion in 2023, then decreased by 23.78% to $1.4 billion in 2024.